{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T13:07:38Z","timestamp":1775567258791,"version":"3.50.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T00:00:00Z","timestamp":1772236800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100013058","name":"Jiangsu Provincial Key Research and Development Program","doi-asserted-by":"publisher","award":["BE2023723"],"award-info":[{"award-number":["BE2023723"]}],"id":[{"id":"10.13039\/501100013058","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"DOI":"10.1186\/s13256-026-05893-4","type":"journal-article","created":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T14:16:48Z","timestamp":1772288208000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Vogt\u2013Koyanagi\u2013Harada-like uveitis with severe hyalitis during treatment by anti-programmed death 1 antibody for lung cancer: a case report"],"prefix":"10.1186","volume":"20","author":[{"given":"Xuanli","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunfeng","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peirong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunhai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4251-6171","authenticated-orcid":false,"given":"Wei","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,28]]},"reference":[{"key":"5893_CR1","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443\u201354.","journal-title":"N Engl J Med"},{"key":"5893_CR2","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.preteyeres.2016.02.002","volume":"52","author":"L Du","year":"2016","unstructured":"Du L, Kijlstra A, Yang P. Vogt\u2013Koyanagi\u2013Harada disease: novel insights into pathophysiology, diagnosis and treatment. Prog Retin Eye Res. 2016;52:84\u2013111.","journal-title":"Prog Retin Eye Res"},{"key":"5893_CR3","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1002\/ccr3.911","volume":"5","author":"T Matsuo","year":"2017","unstructured":"Matsuo T, Yamasaki O. Vogt\u2013Koyanagi\u2013Harada disease-like posterior uveitis in the course of nivolumab (anti-PD-1 antibody), interposed by vemurafenib (BRAF inhibitor), for metastatic cutaneous malignant melanoma. Clin Case Rep. 2017;5:694\u2013700.","journal-title":"Clin Case Rep"},{"key":"5893_CR4","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1097\/CJI.0000000000000154","volume":"40","author":"M Bricout","year":"2017","unstructured":"Bricout M, Petre A, Amini-Adle M, Bezza W, Seve P, Kodjikian L, Dalle S, Thomas L. Vogt\u2013Koyanagi\u2013Harada-like syndrome complicating pembrolizumab treatment for metastatic melanoma. J Immunother. 2017;40:77\u201382.","journal-title":"J Immunother"},{"key":"5893_CR5","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1159\/000496682","volume":"10","author":"S Obata","year":"2019","unstructured":"Obata S, Saishin Y, Teramura K, Ohji M. Vogt\u2013Koyanagi\u2013Harada disease-like uveitis during nivolumab (anti-PD-1 antibody) treatment for metastatic cutaneous malignant melanoma. Case Rep Ophthalmol. 2019;10:67\u201374.","journal-title":"Case Rep Ophthalmol"},{"key":"5893_CR6","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s10633-021-09862-8","volume":"144","author":"GE Hwang","year":"2022","unstructured":"Hwang GE, Lee JW, Jeon S, Cho IH, Kim HD. Vogt\u2013Koyanagi\u2013Harada syndrome-like uveitis after nivolumab administration as a treatment for ovarian cancer. Doc Ophthalmol. 2022;144:153\u201362.","journal-title":"Doc Ophthalmol"},{"key":"5893_CR7","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s10633-020-09800-0","volume":"142","author":"H Enomoto","year":"2021","unstructured":"Enomoto H, Kato K, Sugawara A, Itabashi M, Kondo M. Case with metastatic cutaneous malignant melanoma that developed Vogt\u2013Koyanagi\u2013Harada-like uveitis following pembrolizumab treatment. Doc Ophthalmol. 2021;142:353\u201360.","journal-title":"Doc Ophthalmol"},{"key":"5893_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-020-01519-5","volume":"20","author":"R Kikuchi","year":"2020","unstructured":"Kikuchi R, Kawagoe T, Hotta K. Vogt\u2013Koyanagi\u2013Harada disease-like uveitis following nivolumab administration treated with steroid pulse therapy: a case report. BMC Ophthalmol. 2020;20: 252.","journal-title":"BMC Ophthalmol"},{"key":"5893_CR9","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1111\/1346-8138.14273","volume":"45","author":"T Fujimura","year":"2018","unstructured":"Fujimura T, Kambayashi Y, Tanita K, Sato Y, Hidaka T, Otsuka A, Tanaka H, Furudate S, Hashimoto A, Aiba S. HLA-DRB1*04:05 in two cases of Vogt\u2013Koyanagi\u2013Harada disease-like uveitis developing from an advanced melanoma patient treated by sequential administration of nivolumab and dabrafenib\/trametinib therapy. J Dermatol. 2018;45:735\u20137.","journal-title":"J Dermatol"},{"key":"5893_CR10","doi-asserted-by":"publisher","first-page":"3593","DOI":"10.2169\/internalmedicine.6410-20","volume":"60","author":"R Ushio","year":"2021","unstructured":"Ushio R, Yamamoto M, Miyasaka A, Muraoka T, Kanaoka H, Tamura H, Kaneko A, Izawa A, Hirama N, Teranishi S, et al. Nivolumab-induced Vogt\u2013Koyanagi\u2013Harada-like syndrome and adrenocortical insufficiency with long-term survival in a patient with non-small-cell lung cancer. Intern Med. 2021;60:3593\u20138.","journal-title":"Intern Med"},{"key":"5893_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-024-03484-9","volume":"24","author":"JN Wang","year":"2024","unstructured":"Wang JN, Zhang Y, Huang CY, Li K, Yu XB. Development of Vogt\u2013Koyanagi\u2013Harada disease-like uveitis during treatment by anti-programmed death-1 antibody: a case report. BMC Ophthalmol. 2024;24: 240.","journal-title":"BMC Ophthalmol"},{"key":"5893_CR12","volume":"15","author":"P Giannakis","year":"2023","unstructured":"Giannakis P, Malik M, Rashid S, Vrizidou E. Unilateral posterior uveitis in a patient receiving nivolumab for malignant melanoma. Cureus. 2023;15: e43311.","journal-title":"Cureus"},{"key":"5893_CR13","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1097\/ICB.0000000000001165","volume":"17","author":"CC Ng","year":"2023","unstructured":"Ng CC, Ng JC, Johnson RN, McDonald HR, Agarwal A. Nivolumab-induced Harada-like uveitis with bacillary detachment mimicking choroidal metastasis. Retin Cases Brief Rep. 2023;17:233\u20138.","journal-title":"Retin Cases Brief Rep"},{"key":"5893_CR14","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, Chau I, Ernstoff MS, Gardner JM, Ginex P, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2018;36:1714\u201368.","journal-title":"J Clin Oncol"},{"key":"5893_CR15","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1111\/ced.14282","volume":"45","author":"S Yoshida","year":"2020","unstructured":"Yoshida S, Shiraishi K, Mito T, Sayama K. Vogt\u2013Koyanagi\u2013Harada-like syndrome induced by immune checkpoint inhibitors in a patient with melanoma. Clin Exp Dermatol. 2020;45:908\u201311.","journal-title":"Clin Exp Dermatol"},{"key":"5893_CR16","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1097\/ICB.0000000000001065","volume":"16","author":"GJ Manayath","year":"2022","unstructured":"Manayath GJ, Kuthirummal N, Ranjan R, Verghese S, Venkatapathy N. Atypical central serous chorioretinopathy with choroidal detachment: a case report. Retin Cases Brief Rep. 2022;16:735\u20139.","journal-title":"Retin Cases Brief Rep"},{"key":"5893_CR17","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/S0002-9394(98)00033-6","volume":"125","author":"Y Maruyama","year":"1998","unstructured":"Maruyama Y, Kimura Y, Kishi S, Shimizu K. Serous detachment of the ciliary body in Harada disease. Am J Ophthalmol. 1998;125:666\u201372.","journal-title":"Am J Ophthalmol"},{"key":"5893_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-024-03764-4","volume":"24","author":"M Ozbek","year":"2024","unstructured":"Ozbek M, Aydin R, Artunay O. Management of persistent exudative retinal detachment: exploring etiology and surgical outcomes. BMC Ophthalmol. 2024;24: 493.","journal-title":"BMC Ophthalmol"},{"key":"5893_CR19","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1097\/ICB.0000000000001402","volume":"18","author":"MG Dallinga","year":"2024","unstructured":"Dallinga MG, Bolhuis K, Bins A, de Hoog J. Bilateral diffuse uveal melanocytic proliferation mistaken for nivolumab-induced VKH-like syndrome. Retin Cases Brief Rep. 2024;18:332\u20136.","journal-title":"Retin Cases Brief Rep"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-026-05893-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-026-05893-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-026-05893-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T12:33:26Z","timestamp":1775565206000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13256-026-05893-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,28]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5893"],"URL":"https:\/\/doi.org\/10.1186\/s13256-026-05893-4","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,28]]},"assertion":[{"value":"26 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the ethics committee of the First Affiliated hospital of Soochow University, Soochow, China. The performance of this study was followed the tenets of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"163"}}